1RY0, 1RY8, 1S1P, 1S1R, 1S2A, 1S2C, 1XF0, 1ZQ5, 2F38, 2FGB, 3R43, 3R58, 3R6I, 3R7M, 3R8G, 3R8H, 3R94, 3UFY, 3UG8, 3UGR, 3UWE, 4DBS, 4DBU, 4DBW, 4DZ5, 4FA3, 4FAL, 4FAM, 4H7C, 4HMN, 4WDT, 4WDU, 4WDW, 4WDX, 4WRH, 4XVD, 4XVE, 4ZFC, 4YVX, 4YVV8644105349ENSG00000196139ENSMUSG00000021214P42330Q8K023NM_003739NM_001253908NM_001253909NM_016253NM_134066NM_001346535NP_001240837NP_001240838NP_003730NP_001333464NP_598827Aldo-keto reductase family 1 member C3 (AKR1C3), also known as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5, HSD17B5) or 3α-hydroxysteroid dehydrogenase type 2 (3α-HSD2)[5][6][7] is a steroidogenic enzyme that in humans is encoded by the AKR1C3 gene.

[8][9][10] This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins.

These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors.

The enzymes display overlapping but distinct substrate specificity.

In addition, AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.